Seminars in Arthritis and Rheumatism
Volume 40, Issue 4 , Pages 314-323 , February 2011

Systematic Review on the Effectiveness of Immunosuppressants and Biological Therapies in the Treatment of Autoimmune Posterior Uveitis

  • Esperanza Pato, MD

      Affiliations

    • Rheumatology Department, Hospital Clínico San Carlos, Madrid, Spain
    • Corresponding Author InformationAddress reprint requests to Dra. Esperanza Pato, Servicio de Reumatología, Hospital Clínico San Carlos, Calle Martín Lagos, s/n, 28043 Madrid, Spain
    • ,
  • Santiago Muñoz-Fernández, MD, PhD

      Affiliations

    • Rheumatology Department, Hospital Infanta Sofía, San Sebastián de los Reyes, Madrid, Spain
    • ,
  • Félix Francisco, MD

      Affiliations

    • Rheumatology Department, Hospital Dr. Negrín, Las Palmas de Gran Canaria, Spain
    • ,
  • Miguel A. Abad, MD

      Affiliations

    • Rheumatology Department, Hospital Virgen del Puerto, Plasencia, Spain
    • ,
  • Jesús Maese, MD

      Affiliations

    • Grupo SER de revisores, Madrid, Spain
    • ,
  • Ana Ortiz, MD, PhD

      Affiliations

    • Rheumatology Department, Hospital de la Princesa, Madrid, Spain
    • ,
  • Loreto Carmona, MD, PhD

      Affiliations

    • Research Unit, Sociedad Española de Reumatología, Madrid, Spain
    • ,
  • Uveitis Working Group from Spanish Society of Rheumatology

References 

  1. Yeh S, Faia LJ, Nussenblatt RB. Advances in the diagnosis and immunotherapy for ocular inflammatory disease. Semin Immunopathol. 2008;30(2):145–164
  2. Suttorp-Schulten MS, Rothova A. The possible impact of uveitis in blindness: a literature survey. Br J Ophthalmol. 1996;80(9):844–848
  3. Banares A, Jover JA, Fernandez-Gutierrez B, Benitez del Castillo JM, Garcia J, Vargas E, et al. Patterns of uveitis as a guide in making rheumatologic and immunologic diagnoses. Arthritis Rheum. 1997;40(2):358–370
  4. Jabs DA, Rosenbaum JT, Foster CS, Holland GN, Jaffe GJ, Louie JS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 2000;130(4):492–513
  5. Lustig MJ, Cunningham ET. Use of immunosuppressive agents in uveitis. Curr Opin Ophthalmol. 2003;14(6):399–412
  6. Kim EC, Foster CS. Immunomodulatory therapy for the treatment of ocular inflammatory disease: evidence-based medicine recommendations for use. Int Ophthalmol Clin. 2006;46(2):141–164
  7. Hogan MJ, Kimura SJ, Thygeson P. Signs and symptoms of uveitis (I. Anterior uveitis). Am J Ophthalmol. 1959;47(5 Part 2):155–170
  8. Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data (Results of the First International Workshop). Am J Ophthalmol. 2005;140(3):509–516
  9. Nussenblatt RB, Palestine AG, Chan CC, Roberge F. Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology. 1985;92(4):467–471
  10. Oxford Centre for evidence-based medicine levels of evidence (May 2001). BJU Int. 2009;104(11):1825
  11. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials. 1996;17(1):1–12
  12. BenEzra D, Cohen E, Chajek T, Friedman G, Pizanti S, de Courten C, et al. Evaluation of conventional therapy versus cyclosporine A in Behcet's syndrome. Transplant Proc. 1988;20(3 Suppl 4):136–143
  13. de Smet MD, Rubin BI, Whitcup SM, Lopez JS, Austin HA, Nussenblatt RB. Combined use of cyclosporine and ketoconazole in the treatment of endogenous uveitis. Am J Ophthalmol. 1992;113(6):687–690
  14. de Vries J, Baarsma GS, Zaal MJ, Boen-Tan TN, Rothova A, Buitenhuis HJ, et al. Cyclosporin in the treatment of severe chronic idiopathic uveitis. Br J Ophthalmol. 1990;74(6):344–349
  15. Masuda K, Nakajima A, Urayama A, Nakae K, Kogure M, Inaba G. Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behcet's disease. Lancet. 1989;1(8647):1093–1096
  16. Murphy CC, Greiner K, Plskova J, Duncan L, Frost NA, Forrester JV, et al. Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis. Arch Ophthalmol. 2005;123(5):634–641
  17. Nussenblatt RB, Palestine AG, Chan CC, Stevens G, Mellow SD, Green SB. Randomized, double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis. Am J Ophthalmol. 1991;112(2):138–146
  18. Nussenblatt RB, de Smet MD, Rubin B, Freidlin V, Whitcup SM, Davis J, et al. A masked, randomized, dose-response study between cyclosporine A and G in the treatment of sight-threatening uveitis of noninfectious origin. Am J Ophthalmol. 1993;115(5):583–591
  19. Ramadan AM, Nussenblatt RB, de Smet MD. Long-term follow-up of patients with chronic uveitis affecting the posterior pole treated with combination cyclosporine and ketoconazole. Ophthalmology. 1997;104(4):706–711
  20. Ozyazgan Y, Yurdakul S, Yazici H, Tuzun B, Iscimen A, Tuzun Y, et al. Low dose cyclosporin A versus pulsed cyclophosphamide in Behcet's syndrome: a single masked trial. Br J Ophthalmol. 1992;76(4):241–243
  21. Araujo AA, Wells AP, Dick AD, Forrester JV. Early treatment with cyclosporin in serpiginous choroidopathy maintains remission and good visual outcome. Br J Ophthalmol. 2000;84(9):979–982
  22. BenEzra D, Cohen E, Rakotomalala M, de Courten C, Harris W, Chajek T, et al. Treatment of endogenous uveitis with cyclosporine A. Transplant Proc. 1988;20(3 Suppl 4):122–127
  23. Binder AI, Graham EM, Sanders MD, Dinning W, James DG, Denman AM. Cyclosporin A in the treatment of severe Behcet's uveitis. Br J Rheumatol. 1987;26(4):285–291
  24. Caspers-Velu LE, Decaux G, Libert J. Cyclosporine in Behcet's disease resistant to conventional therapy. Ann Ophthalmol. 1989;21(3):111–168
  25. Graham EM, Sanders MD, James DG, Hamblin A, Kasp Grochowska E, Dumonde D. Cyclosporin A in the treatment of posterior uveitis. Trans Ophthalmol Soc UK. 1985;104(Pt 2):146–151
  26. Le Hoang P, Girard B, Deray G, Le Minh H, De Kozak Y, Thillaye B, et al. Cyclosporine in the treatment of birdshot retinochoroidopathy. Transplant Proc. 1988;20(3 Suppl 4):128–130
  27. Ozdal PC, Ortac S, Taskintuna I, Firat E. Long-term therapy with low dose cyclosporin A in ocular Behcet's disease. Doc Ophthalmol. 2002;105(3):301–312
  28. Pacor ML, Biasi D, Lunardi C, Cortina P, Caramaschi P, Girelli D, et al. Cyclosporin in Behcet's disease: results in 16 patients after 24 months of therapy. Clin Rheumatol. 1994;13(2):224–227
  29. Palestine AG, Nussenblatt RB, Gelato M. Therapy for human autoimmune uveitis with low-dose cyclosporine plus bromocriptine. Transplant Proc. 1988;20(3 Suppl 4):131–135
  30. Sajjadi H, Soheilian M, Ahmadieh H, Hassanein K, Parvin M, Azarmina M, et al. Low dose cyclosporin-A therapy in Behcet's disease. J Ocul Pharmacol. 1994;10(3):553–560
  31. Secchi AG, Tognon MS, Maselli C. Cyclosporine-A in the treatment of serpiginous choroiditis. Int Ophthalmol. 1990;14(5-6):395–399
  32. Secchi AG, De Rosa C, Pivetti-Pezzi P, Rossi A, De Molfetta V, Tognon S, et al. Open noncontrolled multicenter long-term trial with ciclosporin in endogenous non-infectious uveitis. Ophthalmologica. 1991;202(4):217–224
  33. Sullu Y, Oge I, Erkan D, Ariturk N, Mohajeri F. Cyclosporin-A therapy in severe uveitis of Behcet's disease. Acta Ophthalmol Scand. 1998;76(1):96–99
  34. Towler HM, Cliffe AM, Whiting PH, Forrester JV. Low dose cyclosporin A therapy in chronic posterior uveitis. Eye. 1989;3(Pt 3):282–287
  35. Towler HM, Whiting PH, Forrester J, et al. Combination low dose cyclosporin a and steroid therapy in chronic intraocular inflammation. Eye. 1990;4(3):514–520
  36. Towler HM, Lightman SL, Forrester JV. Low-dose cyclosporin therapy of ocular inflammation: preliminary report of a long-term follow-up study. J Autoimmun. 1992;5(Suppl A):259–264
  37. Agarwal M, Ganesh SK, Biswas J. Triple agent immunosuppressive therapy in Vogt-Koyanagi-Harada syndrome. Ocul Immunol Inflamm. 2006;14(6):333–339
  38. Atmaca LS, Batioglu F. The efficacy of cyclosporin-a in the treatment of Behcet's disease. Ophthalmic Surg. 1994;25(5):321–327
  39. Dees C, Arnold JJ, Forrester JV, Dick AD. Immunosuppressive treatment of choroidal neovascularization associated with endogenous posterior uveitis. Arch Ophthalmol. 1998;116(11):1456–1461
  40. Dios Castro E, Herreras Cantalapiedra JM, Calonge Cano M, Oses S. Ocular sarcoidosis (Retrospective study of 18 cases). Arch Soc Esp Oftalmol. 2002;77(6):301–308
  41. Hakin KN, Pearson RV, Lightman SL. Sympathetic ophthalmia: visual results with modern immunosuppressive therapy. Eye. 1992;6(Pt 5):453–455
  42. Hayasaka S, Kawamoto K, Noda S, Kodama T. Visual prognosis in patients with Behcet's disease receiving colchicine, systemic corticosteroid or cyclosporin. Ophthalmologica. 1994;208(4):210–213
  43. Kilmartin DJ, Forrester JV, Dick AD. Cyclosporin A therapy in refractory non-infectious childhood uveitis. Br J Ophthalmol. 1998;82(7):737–742
  44. Kiss S, Ahmed M, Letko E, Foster CS. Long-term follow-up of patients with birdshot retinochoroidopathy treated with corticosteroid-sparing systemic immunomodulatory therapy. Ophthalmology. 2005;112(6):1066–1071
  45. Menezo V, Lau C, Comer M, Lightman S. Clinical outcome of chronic immunosuppression in patients with non-infectious uveitis. Clin Exp Ophthalmol. 2005;33(1):16–21
  46. Michel SS, Ekong A, Baltatzis S, Foster CS. Multifocal choroiditis and panuveitis: immunomodulatory therapy. Ophthalmology. 2002;109(2):378–383
  47. Muftuoglu AU, Pazarli H, Yurdakul S, Yazici H, Ulku BY, Tuzun Y, et al. Short term cyclosporin A treatment of Behcet's disease. Br J Ophthalmol. 1987;71(5):387–390
  48. Nussenblatt RB, Palestine AG, Rook AH, Scher I, Wacker WB, Gery I. Treatment of intraocular inflammatory disease with cyclosporin A. Lancet. 1983;30(2(8344):235–238
  49. Nussenblatt RB, Palestine AG, Chan CC. Cyclosporin A therapy in the treatment of intraocular inflammatory disease resistant to systemic corticosteroids and cytotoxic agents. Am J Ophthalmol. 1983;96(3):275–282
  50. Paredes I, Ahmed M, Foster CS. Immunomodulatory therapy for Vogt-Koyanagi-Harada patients as first-line therapy. Ocul Immunol Inflamm. 2006;14(2):87–90
  51. Pascalis L, Pia G, Aresu G, Frongia T, Barca L. Combined cyclosporin A-steroid-MTX treatment in endogenous non-infectious uveitis. J Autoimmun. 1993;6(4):467–480
  52. Vitale AT, Rodriguez A, Foster CS. Low-dose cyclosporine therapy in the treatment of birdshot retinochoroidopathy. Ophthalmology. 1994;101(5):822–831
  53. Vitale AT, Rodriguez A, Foster CS. Low-dose cyclosporin A therapy in treating chronic, noninfectious uveitis. Ophthalmology. 1996;103(3):365–373
  54. Wakefield D, McCluskey P. Cyclosporine: a therapy in inflammatory eye disease. J Ocul Pharmacol. 1991;7(3):221–226
  55. Walton RC, Nussenblatt RB, Whitcup SM. Cyclosporine therapy for severe sight-threatening uveitis in children and adolescents. Ophthalmology. 1998;105(11):2028–2034
  56. Whitcup SM, Salvo ECJ, Nussenblatt RB. Combined cyclosporine and corticosteroid therapy for sight-threatening uveitis in Behcet's disease. Am J Ophthalmol. 1994;118(1):39–45
  57. Yu EN, Meniconi ME, Tufail F, Baltatzis S, Foster CS. Outcomes of treatment with immunomodulatory therapy in patients with corticosteroid-resistant juvenile idiopathic arthritis-associated chronic iridocyclitis. Ocul Immunol Inflamm. 2005;13(5):353–360
  58. Mochizuki M, Masuda K, Sakane T, Inaba G, Ito K, Kogure M, et al. A multicenter clinical open trial of FK 506 in refractory uveitis, including Behcet's disease (Japanese FK 506 Study Group on Refractory Uveitis). Transplant Proc. 1991;23(6):3343–3346
  59. Mochizuki M, Masuda K, Sakane T, Ito K, Kogure M, Sugino N, et al. A clinical trial of FK506 in refractory uveitis. Am J Ophthalmol. 1993;115(6):763–769
  60. Figueroa MS, Ciancas E, Orte L. Long-term follow-up of tacrolimus treatment in immune posterior uveitis. Eur J Ophthalmol. 2007;17(1):69–74
  61. Ishioka M, Ohno S, Nakamura S, Isobe K, Watanabe N, Ishigatsubo Y, et al. FK506 treatment of noninfectious uveitis. Am J Ophthalmol. 1994;118(6):723–729
  62. Sloper CM, Powell RJ, Dua HS. Tacrolimus (FK506) in the treatment of posterior uveitis refractory to cyclosporine. Ophthalmology. 1999;106(4):723–728
  63. Hogan AC, McAvoy CE, Dick AD, Lee RW. Long-term efficacy and tolerance of tacrolimus for the treatment of uveitis. Ophthalmology. 2007;114(5):1000–1006
  64. Kilmartin DJ, Forrester JV, Dick AD. Tacrolimus (FK506) in failed cyclosporin A therapy in endogenous posterior uveitis. Ocul Immunol Inflam. 1998;6(2):101–109
  65. Davatchi F, Shahram F, Chams H, Jamshidi AR, Nadji A, Chams C, et al. High dose methotrexate for ocular lesions of Behcet's disease (Preliminary short-term results). Adv Exp Med Biol. 2003;528:579–584
  66. Dev S, McCallum RM, Jaffe GJ. Methotrexate treatment for sarcoid-associated panuveitis. Ophthalmology. 1999;106(1):111–118
  67. Foeldvari I, Wierk A. Methotrexate is an effective treatment for chronic uveitis associated with juvenile idiopathic arthritis. J Rheumatol. 2005;32(2):362–365
  68. Kaplan-Messas A, Barkana Y, Avni I, Neumann R. Methotrexate as a first-line corticosteroid-sparing therapy in a cohort of uveitis and scleritis. Ocul Immunol Inflamm. 2003;11(2):131–139
  69. Lazar M, Weiner MJ, Leopold IH. Treatment of uveitis with methotrexate. Am J Ophthalmol. 1969;67(3):383–387
  70. Malik AR, Pavesio C. The use of low dose methotrexate in children with chronic anterior and intermediate uveitis. Br J Ophthalmol. 2005;89(7):806–808
  71. Samson CM, Waheed N, Baltatzis S, Foster CS. Methotrexate therapy for chronic noninfectious uveitis: analysis of a case series of 160 patients. Ophthalmology. 2001;108(6):1134–1139
  72. Shetty AK, Zganjar BE, Ellis GSJ, Ludwig IH, Gedalia A. Low-dose methotrexate in the treatment of severe juvenile rheumatoid arthritis and sarcoid iritis. J Pediatr Ophthalmol Strabismus. 1999;36(3):125–128
  73. Soheilian M, Aletaha M, Yazdani S, Dehghan MH, Peyman GA. Management of pediatric Vogt-Koyanagi-Harada (VKH)-associated panuveitis. Ocul Immunol Inflamm. 2006;14(2):91–98
  74. Weiss AH, Wallace CA, Sherry DD. Methotrexate for resistant chronic uveitis in children with juvenile rheumatoid arthritis. J Pediatr. 1998;133(2):266–268
  75. Mathews JD, Crawford BA, Bignell JL, Mackay IR. Azathioprine in active chronic iridocyclitis (A double-blind controlled trial). Br J Ophthalmol. 1969;53(5):327–330
  76. Yazici H, Pazarli H, Barnes CG, Tuzun Y, Ozyazgan Y, Silman A, et al. A controlled trial of azathioprine in Behcet's syndrome. N Engl J Med. 1990;322(5):281–285
  77. Andrasch RH, Pirofsky B, Burns RP. Immunosuppressive therapy for severe chronic uveitis. Arch Ophthalmol. 1978;96(2):247–251
  78. Bietti GB, Cerulli L, Pivetti-Pezzi P. Behcet's disease and immunosuppressive treatment. Our personal experience Mod Probl Ophthalmol. 1976;16:314–323
  79. Cuchacovich M, Pacheco P, Diaz G, Rojas B, Stoppel J, Merino G, et al. Role of Azathioprine in steroid resistant non infectious ocular inflammatory diseases. Rev Med Chil. 2007;135(6):702–707
  80. Hamuryudan V, Ozyazgan Y, Hizli N, Mat C, Yurdakul S, Tuzun Y, et al. Azathioprine in Behcet's syndrome: effects on long-term prognosis. Arthritis Rheum. 1997;40(4):769–774
  81. Schatz CS, Uzel JL, Leininger L, Danner S, Terzic J, Fischbach M. Immunosuppressants used in a steroid-sparing strategy for childhood uveitis. J Pediatr Ophthalmol Strabismus. 2007;44(1):28–34
  82. Vianna RN, Ozdal PC, Deschenes J, Burnier MNJ. Combination of azathioprine and corticosteroids in the treatment of serpiginous choroiditis. Can J Ophthalmol. 2006;41(2):183–189
  83. Kilmartin DJ, Forrester JV, Dick AD. Rescue therapy with mycophenolate mofetil in refractory uveitis. Lancet. 1998;352(9121):35–36
  84. Larkin G, Lightman S. Mycophenolate mofetil (A useful immunosuppressive in inflammatory eye disease). Ophthalmology. 1999;106(2):370–374
  85. Doycheva D, Deuter C, Stuebiger N, Biester S, Zierhut M. Mycophenolate mofetil in the treatment of uveitis in children. Br J Ophthalmol. 2007;91(2):180–184
  86. Lau CH, Comer M, Lightman S. Long-term efficacy of mycophenolate mofetil in the control of severe intraocular inflammation. Clin Exp Ophthalmol. 2003;31(6):487–491
  87. Siepmann K, Huber M, Stubiger N, Deuter C, Zierhut M. Mycophenolate mofetil is a highly effective and safe immunosuppressive agent for the treatment of uveitis : a retrospective analysis of 106 patients. Graefes Arch Clin Exp Ophthalmol. 2006;244(7):788–794
  88. Thorne JE, Jabs DA, Qazi FA, Nguyen QD, Kempen JH, Dunn JP. Mycophenolate mofetil therapy for inflammatory eye disease. Ophthalmology. 2005;112(8):1472–1477
  89. Abdalla MI, el-D Bahoat N. Long-lasting remission of Behcet's disease after chlorambucil therapy. Br J Ophthalmol. 1973;57(9):706–711
  90. Godfrey WA, Epstein WV, O'Connor GR, Kimura SJ, Hogan MJ, Nozik RA. The use of chlorambucil in intractable idiopathic uveitis. Am J Ophthalmol. 1974;78(3):415–428
  91. Tessler HH, Jennings T. High-dose short-term chlorambucil for intractable sympathetic ophthalmia and Behcet's disease. Br J Ophthalmol. 1990;74(6):353–357
  92. Akpek EK, Jabs DA, Tessler HH, Joondeph BC, Foster CS. Successful treatment of serpiginous choroiditis with alkylating agents. Ophthalmology. 2002;109(8):1506–1513
  93. Elliott JH, Ballinger WH. Behcet's syndrome: treatment with chlorambucil. Trans Am Ophthalmol Soc. 1984;82:264–281
  94. Jennings T, Tessler HH. Twenty cases of sympathetic ophthalmia. Br J Ophthalmol. 1989;73(2):140–145
  95. Miserocchi E, Baltatzis S, Ekong A, Roque M, Foster CS. Efficacy and safety of chlorambucil in intractable noninfectious uveitis: the Massachusetts Eye and Ear Infirmary experience. Ophthalmology. 2002;109(1):137–142
  96. Mudun BA, Ergen A, Ipcioglu SU, Burumcek EY, Durlu Y, Arslan MO. Short-term chlorambucil for refractory uveitis in Behcet's disease. Ocul Immunol Inflamm. 2001;9(4):219–229
  97. O'Duffy JD, Robertson DM, Goldstein NP. Chlorambucil in the treatment of uveitis and meningoencephalitis of Behcet's disease. Am J Med. 1984;76(1):75–84
  98. Tricoulis D. Treatment of Behcet's disease with chlorambucil. Br J Ophthalmol. 1976;60(1):55–57
  99. Durrani K, Papaliodis GN, Foster CS. Pulse IV cyclophosphamide in ocular inflammatory disease: efficacy and short-term safety. Ophthalmology. 2004;111(5):960–965
  100. Suhler EB, Smith JR, Wertheim MS, Lauer AK, Kurz DE, Pickard TD, et al. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch Ophthalmol. 2005;123(7):903–912
  101. Abu El-Asrar AM, Abboud EB, Aldibhi H, Al-Arfaj A. Long-term safety and efficacy of infliximab therapy in refractory uveitis due to Behcet's disease. Int Ophthalmol. 2005;26(3):83–92
  102. Accorinti M, Pirraglia MP, Paroli MP, Priori R, Conti F, Pivetti-Pezzi P. Infliximab treatment for ocular and extraocular manifestations of Behcet's disease. Jpn J Ophthalmol. 2007;51(3):191–196
  103. Arayssi T, Hamra R, Homeidan F, Uthman I, Awwad ST, Mroue K, et al. The efficacy of a single dose of infliximab in the treatment of Behcet's disease uveitis. Clin Exp Rheumatol 427;23(3):427.
  104. Benitez-del-Castillo JM, Martinez-de-la-Casa JM, Pato-Cour E, Mendez-Fernandez R, Lopez-Abad C, Matilla M, et al. Long-term treatment of refractory posterior uveitis with anti-TNFalpha (infliximab). Eye. 2005;19(8):841–845
  105. Cobo-Ibanez T, Munoz-Fernandez S, Hidalgo-Barrero V, Martin-Mola E. Medium-long term treatment with infliximab and methotrexate in posterior and/or chronic uveitis refractory to conventional treatment. Med Clin (Barc). 2006;126(1):34–3514
  106. Foeldvari I, Nielsen S, Kummerle-Deschner J, Espada G, Horneff G, Bica B, et al. Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey. J Rheumatol. 2007;34(5):1146–1150
  107. Joseph A, Raj D, Dua HS, Powell PT, Lanyon PC, Powell RJ. Infliximab in the treatment of refractory posterior uveitis. Ophthalmology. 2003;110(7):1449–1453
  108. Lindstedt EW, Baarsma GS, Kuijpers RW, van Hagen PM. Anti-TNF-alpha therapy for sight threatening uveitis. Br J Ophthalmol. 2005;89(5):533–536
  109. Markomichelakis NN, Theodossiadis PG, Pantelia E, Papaefthimiou S, Theodossiadis GP, Sfikakis PP. Infliximab for chronic cystoid macular edema associated with uveitis. Am J Ophthalmol. 2004;138(4):648–650
  110. Merino G, Varas G, Diaz G, Gutierrez M, Massardo L, Pacheco D, et al. Effectiveness of infliximab in patients with Behcet syndrome and severe uveoretinitis (Report of five cases). Rev Med Chil. 2006;134(7):875–882
  111. Nakamura S, Ohno S. Anti-tumor necrosis factor alpha antibody in the treatment of Behcet's disease. Int Ophthalmol Clin. 2005;45(2):179–189
  112. Niccoli L, Nannini C, Benucci M, Chindamo D, Cassara E, Salvarani C, et al. Long-term efficacy of infliximab in refractory posterior uveitis of Behcet's disease: a 24-month follow-up study. Rheumatology (Oxford). 2007;46(7):1161–1164
  113. Sfikakis PP, Kaklamanis PH, Elezoglou A, Katsilambros N, Theodossiadis PG, Papaefthimiou S, et al. Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behcet disease. Ann Intern Med. 2004;140(5):404–406
  114. Sfikakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P, Markomichelakis NN. Effect of infliximab on sight-threatening panuveitis in Behcet's disease. Lancet. 2001;358(9278):295–296
  115. Tugal-Tutkun I, Mudun A, Urgancioglu M, Kamali S, Kasapoglu E, Inanc M, et al. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behcet's disease: an open-label trial. Arthritis Rheum. 2005;52(8):2478–2484
  116. Bodaghi B, Bui Quoc E, Wechsler B, Tran TH, Cassoux N, Le Thi Huong D, et al. Therapeutic use of infliximab in sight threatening uveitis: retrospective analysis of efficacy, safety, and limiting factors. Ann Rheum Dis. 2005;64(6):962–964
  117. Galor A, Perez VL, Hammel JP, Lowder CY. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation. Ophthalmology. 2006;113(12):2317–2323
  118. Gallagher M, Quinones K, Cervantes-Castaneda RA, Yilmaz T, Foster C, et al. Biological response modifier therapy for refractory childhood uveitis. Br J Ophthalmol. 2007;91(10):1341–1344
  119. Kahn P, Weiss M, Imundo LF, Levy DM. Favorable response to high-dose infliximab for refractory childhood uveitis. Ophthalmology. 2006;113(5):860–864.e2
  120. Lanthier N, Parc C, Scavennec R, Dhote R, Brezin AP, Guillevi L, et al. Infliximab in the treatment of posterior uveitis in behcet's disease: long term follow up in four patients. Presse Med. 2005;34(13):916–918
  121. Murphy CC, Ayliffe WH, Booth A, Makanjuola D, Andrews PA, Jayne D. Tumor necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis. Ophthalmology. 2004;111(2):352–356
  122. Rajaraman RT, Kimura Y, Li S, Haines K, Chu DS. Retrospective case review of pediatric patients with uveitis treated with infliximab. Ophthalmology. 2006;113(2):308–314
  123. Richards JC, Tay-Kearney ML, Murray K, Manners P. Infliximab for juvenile idiopathic arthritis-associated uveitis. Clin Exp Ophthalmol. 2005;33(5):461–468
  124. Saurenmann RK, Levin AV, Rose JB, Parker S, Rabinovitch T, Tyrrell PN, et al. Tumour necrosis factor alpha inhibitors in the treatment of childhood uveitis. Rheumatology (Oxford). 2006;45(8):982–989
  125. Sharma SM, Ramanan AV, Riley P, Dick AD. Use of infliximab in juvenile onset rheumatological disease-associated refractory uveitis: efficacy in joint and ocular disease. Ann Rheum Dis. 2007;66(6):840–841
  126. Smith JR, Levinson RD, Holland GN, Jabs DA, Robinson MR, Whitcup SM, et al. Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis Rheum. 2001;45(3):252–257
  127. Sobrin L, Kim EC, Christen W, Papadaki T, Letko E, Foster CS. Infliximab therapy for the treatment of refractory ocular inflammatory disease. Arch Ophthalmol. 2007;125(7):895–900
  128. Tynjala P, Lindahl P, Honkanen V, Lahdenne P, Kotaniemi K. Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis. Ann Rheum Dis. 2007;66(4):548–550
  129. Wechsler B, Sable-Fourtassou R, Bodaghi B, Huong DL, Cassoux N, Badelon I, et al. Infliximab in refractory uveitis due to Behcet's disease. Clin Exp Rheumatol. 2004;22(4 Suppl 34):S14–S16
  130. Foster CS, Tufail F, Waheed NK, Chu D, Miserocchi E, Baltatzis S, et al. Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate. Arch Ophthalmol. 2003;121(4):437–440
  131. Smith JA, Thompson DJ, Whitcup SM, Suhler E, Clarke G, Smith S, et al. A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum. 2005;53(1):18–23
  132. Reiff A, Takei S, Sadeghi S, Stout A, Shaham B, Bernstein B, et al. Etanercept therapy in children with treatment-resistant uveitis. Arthritis Rheum. 2001;44(6):1411–1415
  133. Biester S, Deuter C, Michels H, Haefner R, Kuemmerle-Deschner J, Doycheva D, et al. Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol. 2007;91(3):319–324
  134. Vazquez-Cobian LB, Flynn T, Lehman TJ. Adalimumab therapy for childhood uveitis. J Pediatr. 2006;149(4):572–575
  135. Mushtaq B, Saeed T, Situnayake RD, Murray PI. Adalimumab for sight-threatening uveitis in Behcet's disease. Eye. 2007;21(6):824–825
  136. Buggage RR, Levy-Clarke G, Sen HN, Ursea R, Srivastava SK, Suhler EB, et al. A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Behcet's disease. Ocul Immunol Inflamm. 2007;15(2):63–70
  137. Nussenblatt RB, Fortin E, Schiffman R, Rizzo L, Smith J, Van Veldhuisen P, et al. Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial. Proc Natl Acad Sci USA. 1999;96(13):7462–7466
  138. Nussenblatt RB, Peterson JS, Foster CS, Rao NA, See RF, Letko E, et al. Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis: a multicenter noncomparative interventional case series. Ophthalmology. 2005;112(5):764–770
  139. Nussenblatt RB, Thompson DJ, Li Z, Chan CC, Peterson JS, Robinson RR, et al. Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration. J Autoimmun. 2003;21(3):283–293
  140. Hernandez Garfella ML, Diaz Llopis M, Salom Alonso D, Cervera Taulet E. Recurrent uveitis and therapy with monoclonal antibody (daclizumab). Arch Soc Esp Oftalmol. 2004;79(12):593–598
  141. Papaliodis GN, Chu D, Foster CS. Treatment of ocular inflammatory disorders with daclizumab. Ophthalmology. 2003;110(4):786–789
  142. Deuter CM, Koetter I, Guenaydin I, Stuebiger N, Zierhut M. Interferon alfa-2a: a new treatment option for long lasting refractory cystoid macular edema in uveitis? (A pilot study). Retina. 2006;26(7):786–791
  143. Hamuryudan V, Ozyazgan Y, Fresko Y, Mat C, Yurdakul S, Yazici H. Interferon alfa combined with azathioprine for the uveitis of Behcet's disease: an open study. Isr Med Assoc J. 2002;4(11 Suppl):928–930
  144. Pivetti-Pezzi P, Accorinti M, Pirraglia MP, Priori R, Valesini G. Interferon alpha for ocular Behcet's disease. Acta Ophthalmol Scand. 1997;75(6):720–722
  145. Plskova J, Greiner K, Forrester JV. Interferon-alpha as an effective treatment for noninfectious posterior uveitis and panuveitis. Am J Ophthalmol. 2007;144(1):55–61
  146. Sobaci G, Bayraktar Z, Bayer A. Interferon alpha-2a treatment for serpiginous choroiditis. Ocul Immunol Inflamm. 2005;13(1):59–66
  147. Becker MD, Heiligenhaus A, Hudde T, Storch-Hagenlocher B, Wildemann B, Barisani-Asenbauer T, et al. Interferon as a treatment for uveitis associated with multiple sclerosis. Br J Ophthalmol. 2005;89(10):1254–1257
  148. Bodaghi B, Gendron G, Wechsler B, Terrada C, Cassoux N, Huong du LT, et al. Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients. Br J Ophthalmol. 2007;91(3):335–339
  149. Calguneri M, Ozturk MA, Ertenli I, Kiraz S, Apras S, Ozbalkan Z. Effects of interferon alpha treatment on the clinical course of refractory Behcet's disease: an open study. Ann Rheum Dis. 2003;62(5):492–493
  150. Guillaume-Czitrom S, Berger C, Pajot C, Bodaghi B, Wechsler B, Kone-Paut I. Efficacy and safety of interferon-alpha in the treatment of corticodependent uveitis of paediatric Behcet's disease. Rheumatology (Oxford). 2007;46(10):1570–1573
  151. Tugal-Tutkun I, Guney-Tefekli E, Urgancioglu M. Results of interferon-alfa therapy in patients with Behcet uveitis. Graefes Arch Clin Exp Ophthalmol. 2006;244(12):1692–1695
  152. Kotter I, Gunaydin I, Zierhut M, Stubiger N. The use of interferon alpha in Behcet disease: review of the literature. Semin Arthritis Rheum. 2004;33(5):320–335
  153. Alpsoy E, Durusoy C, Yilmaz E, Ozgurel Y, Ermis O, Yazar S, et al. Interferon alfa-2a in the treatment of Behcet disease: a randomized placebo-controlled and double-blind study. Arch Dermatol. 2002;138(4):467–471
  154. Farber MD, Lam S, Tessler HH, Jennings T, Cross A, Rusin MM. Reduction of macular oedema by acetazolamide in patients with chronic iridocyclitis: a randomised prospective crossover study. Br J Ophthalmol. 1994;78(1):4–7
  155. Lashay AR, Rahimi A, Chams H, Davatchi F, Shahram F, Hatmi ZN, et al. Evaluation of the effect of acetazolamide on cystoid macular oedema in patients with Behcet's disease. Eye. 2003;17(6):762–766
  156. Whitcup SM, Csaky KG, Podgor MJ, Chew EY, Perry CH, Nussenblatt RB. A randomized, masked, cross-over trial of acetazolamide for cystoid macular edema in patients with uveitis. Ophthalmology. 1996;103(7):1054–1062
  157. Cox SN, Hay E, Bird AC. Treatment of chronic macular edema with acetazolamide. Arch Ophthalmol. 1988;106(9):1190–1195
  158. Kotter I, Eckstein AK, Stubiger N, Zierhut M. Treatment of ocular symptoms of Behcet's disease with interferon alpha 2a: a pilot study. Br J Ophthalmol. 1998;82(5):488–494
  159. Kotter I, Zierhut M, Eckstein AK, Vonthein R, Ness T, Gunaydin I, et al. Human recombinant interferon alfa-2a for the treatment of Behcet's disease with sight threatening posterior or panuveitis. Br J Ophthalmol. 2003;87(4):423–431
  160. Murphy CC, Greiner K, Plskova J, Duncan L, Frost A, Isaacs JD, et al. Neutralizing tumor necrosis factor activity leads to remission in patients with refractory noninfectious posterior uveitis. Arch Ophthalmol. 2004;122(6):845–851
  161. Tehrani NN, Saeed T, Murray PI. Deep intramuscular methylprednisolone for the treatment of cystoid macular oedema in uveitis. Eye. 2000;14(Pt 5):691–694
  162. Zierhut M, Thiel HJ, Schlote T. Treatment of uveitic macular edema with acetazolamide. Doc Ophthalmol. 1999;97(3-4):409–413
  163. Schilling H, Heiligenhaus A, Laube T, Bornfeld N, Jurklies B. Long-term effect of acetazolamide treatment of patients with uveitic chronic cystoid macular edema is limited by persisting inflammation. Retina. 2005;25(2):182–188
  164. Wakefield D, McCluskey P, Penny R. Intravenous pulse methylprednisolone therapy in severe inflammatory eye disease. Arch Ophthalmol. 1986;104:847–851
  165. Kacmaz RO, Kempen JH, Newcomb C, Daniel E, Gangaputra S, Nussenblatt RB, et al. Cyclosporine for ocular inflammatory diseases. Ophthalmology. 2010;117(3):576–584
  166. Gangaputra S, Newcomb CW, Liesegang TL, Kacmaz RO, Jabs DA, Levy-Clarke GA, et al. Methotrexate for ocular inflammatory diseases. Ophthalmology. 2009;116(11):2188–2198
  167. Pasadhika S, Kempen JH, Newcomb CW, Liesegang TL, Pujari SS, Rosenbaum JT, et al. Azathioprine for ocular inflammatory diseases. Am J Ophthalmol. 2009;148(4):500–509
  168. Daniel E, Thorne JE, Newcomb CW, Pujari SS, Kacmaz RO, Levy-Clarke GA, et al. Mycophenolate mofetil for ocular inflammation. Am J Ophthalmol. 2010;149(3):423–432
  169. Pujari SS, Kempen JH, Newcomb CW, Gangaputra S, Daniel E, Suhler EB, et al. Cyclophosphamide for ocular inflammatory diseases. Ophthalmology. 2010;117(2):356–365

 Sources of support: Schering Plough, S.A. donated to the Fundación Española de Reumatología to facilitate the review. The Fundación Española de Reumatología provided the personal resources and materials needed for the review.

 The panel of experts of the Uveitis Working Group from the Spanish Society of Rheumatology include the following: David Diaz Valle, MD, PhD; Ma Cruz Fernández Espartero, MD; Jose A. Fernández Sánchez, MD; Angel García Aparício, MD; Estibaliz Loza Santamaría, MD; Roberto Miguelez Sánchez, MD; Carlos Montilla Morales, MD; and Eduardo Úcar Ângulo, MD.

PII: S0049-0172(10)00084-3

doi: 10.1016/j.semarthrit.2010.05.008

Seminars in Arthritis and Rheumatism
Volume 40, Issue 4 , Pages 314-323 , February 2011

Article Tools

* Image Usage & Resolution